Funding & VC

Ansa Biotechnologies Raises $71.5M to Scale DNA Synthesis

Ansa Biotechnologies raised $71.5 million in an oversubscribed Series C led by Blue Water Life Science Advisors, lifting total funding to $211 million after quadrupling manufacturing capacity.

By Grace Kim

4 min read

Ansa Biotechnologies Raises $71.5 Million To Scale DNA Synthesis
Ansa Biotechnologies Raises $71.5 Million To Scale DNA SynthesisColiN00B / pixabay

What's News

  • Ansa Biotechnologies raised $71.5 million in an oversubscribed Series C, bringing total funding to $211 million.
  • Blue Water Life Science Advisors led the round; Illumina Ventures, BEVC, Lightscape Partners and Agent Capital are new investors, and Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures participated again.
  • Ansa offers sequence-perfect clonal DNA up to 50 kilobases plus sequence-verified linear double-stranded DNA fragments, and quadrupled manufacturing capacity during the prior year.
  • Nick Naclerio, Brad Crutchfield and Nate Cornell joined the board; BEVC co-founder Rowan Chapman joined as board observer; Matthew McManus stepped down after three years.
  • Ansa applies biosecurity screening to every order and guarantees shipping dates, giving the customer the order free if it misses the committed date.

Ansa Biotechnologies raised $71.5 million in an oversubscribed Series C, bringing total funding for the DNA synthesis company to $211 million. Blue Water Life Science Advisors led the financing.

Who backed the round?

Four new investors joined: Illumina Ventures, BEVC, Lightscape Partners and Agent Capital. Four existing investors bought in again — Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures.

The company named three uses for the money: expand manufacturing capacity, serve additional customers, and extend its ability to produce long and complex synthetic DNA.

In plain terms: the round buys Ansa more throughput, more customers and longer, harder-to-make sequences.

Capacity already quadrupled

Ansa quadrupled its manufacturing capacity during the prior year in response to customer demand. The new financing funds another stage of operating scale as researchers request longer and more technically challenging sequences.

The sequence length per order is what drives the volume math: a 50-kilobase clonal DNA order carries more work than a short fragment, so capacity has to keep pace with design ambition rather than order count alone.

What Ansa actually sells

Ansa runs an enzymatic synthesis platform built for sequences that traditional methods struggle to make. Conventional techniques, the company says, run into limits on sequence length, complexity, reliability and delivery schedules.

The product line includes sequence-perfect clonal DNA up to 50 kilobases and sequence-verified linear double-stranded DNA fragments. Ansa says those products support drug discovery, vaccines, cell and gene therapies, agrigenomics and other biological research.

Two operating promises come with every order. Ansa applies biosecurity screening to all of them. The company also offers an on-time guarantee: if the complete order fails to ship by the committed date, the customer receives it without charge.

The backdrop is AI-enabled drug discovery and computational biology, which generate increasingly ambitious genetic designs that still have to be manufactured as physical DNA before anyone can test them.

Who joins the board

Three executives joined Ansa's board. Nick Naclerio, founding partner of Illumina Ventures, brings experience in life science company development and commercialization. Brad Crutchfield, an independent director, previously held senior commercial leadership roles at 10x Genomics, Bio-Rad Laboratories, QIAGEN and Illumina. Nate Cornell, Blue Water's founder and chief investment officer, adds more than 25 years of capital markets experience. BEVC co-founder Rowan Chapman joined as a board observer.

Matthew McManus is stepping down after three years on Ansa's board.

What the investors say

Naclerio tied the investment to the design-to-test gap that AI-driven biology creates: "The full potential of AI-enabled biology depends on the ability to build and test what computational models design. Ansa gives researchers access to DNA that has historically been difficult, if not impossible, to obtain, with a delivery commitment they can plan around. That combination of technical capability and commercial execution is why we invested."

Cornell, whose firm led the round, framed it as a scale decision: "We have believed in Ansa's vision to transform DNA synthesis from the beginning, and we're excited to continue supporting the team as they bring that vision to life." He added that "this latest financing round will help the company expand its capabilities and scale operations to meet growing customer demand."

Gammack pointed to what he sees as the commercial proof point: "Researchers are coming to Ansa with increasingly ambitious designs and a straightforward expectation: deliver the DNA. Our growth reflects the demand unlocked when scientists can reliably obtain sequences that previously held their projects back." He added: "This oversubscribed financing validates our commercial success and gives us the resources to expand our capacity, serve more customers, and drive the next generation of biological innovation."

On the board changes, he said: "Nick and Brad have helped build some of the most consequential life science tools businesses. They understand the operational and commercial demands of rapid growth, and their experience will be invaluable as we scale Ansa." On McManus's departure: "Matt has been an important part of Ansa's journey and helped build the foundation for our growing commercial business. We are grateful for his leadership and support over the past three years."

What to watch

Ansa has already expanded capacity fourfold and now says it needs another stage of scale. The open question is whether the 50-kilobase ceiling, the bioscreening on every order and the free-guarantee promise survive an order book where both sequence length and customer count are climbing at once.

Source: pulse2.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,316 articles

Related articles

« Previous article